L3VLUP
ProSign in

XENE · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

XENELLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • XENE
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterXENELLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 20211 holders, $14m24 holders, $23.0bn
Q2 20211 holders, $17m24 holders, $27.8bn
Q3 20212 holders, $20m31 holders, $29.9bn
Q4 20214 holders, $205m31 holders, $34.7bn
Q1 20226 holders, $215m24 holders, $35.3bn
Q2 20227 holders, $230m33 holders, $42.7bn
Q3 20227 holders, $330m31 holders, $43.4bn
Q4 20228 holders, $303m31 holders, $46.6bn
Q1 20239 holders, $259m33 holders, $44.3bn
Q2 20235 holders, $222m37 holders, $59.6bn
Q3 20237 holders, $220m44 holders, $67.6bn
Q4 202311 holders, $590m45 holders, $73.6bn
Q1 20246 holders, $396m41 holders, $95.3bn
Q2 20247 holders, $383m43 holders, $110bn
Q3 20247 holders, $428m45 holders, $107bn
Q4 20246 holders, $400m46 holders, $93.9bn
Q1 20255 holders, $343m42 holders, $98.4bn
Q2 20255 holders, $224m43 holders, $93.2bn
Q3 20255 holders, $415m39 holders, $86.7bn
Q4 20256 holders, $501m41 holders, $123bn
Q1 20268 holders, $1.3bn39 holders, $106bn
Q2 20269 holders, $1.2bn44 holders, $132bn
XENE

Xenon Pharmaceuticals Inc

Holders
8
Reported value
$1.3bn
Buyers
22
Sellers
9

Breadth +13 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only XENE (0)

None.

Only LLY (31)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Soros Fund Management LLC, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →